Skip to main content

Table 3 Selected series of SBRT for primary NSCLC and/or metastatic lung tumors

From: A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer

Authors P/M No. of patients Dose/fractions LC PFS/OS
All P M From CRC P/M CRC P/M CRC
Oh et al. 2012 [45] M 57 33 24 7 50Gy/5f, 60Gy/5f, 60Gy/4f 3-y: 94.5% 3-y: 80.0% 2-y DFS: 59.7%  
Binkley et al. 2015 [40] M 77    26 25Gy/1f,
50Gy/4f
1-y: 91.3%;
2-y: 83.8%
1-y: 74.5%;
2-y: 57.8%
2-y OS: 74.7%,  
Agolli et al. 2016 [42] M     44 23Gy/1f
30Gy/1f
45Gy/3f
  1-y: 68.8%;
2-y: 60.2%
3-y: 54.2%
  2-y OS: 67.7%;
3-y OS: 50.8%
2-y PFS: 20.3%
Thibault et al. 2014 [44] P/M 254    45 48-60Gy/4-5f 2-y: 96% (P) 2-y: 76%   
Qiu et al. 2015 [43] M     65 50Gy/5-10f   2-y: 30%   2-y OS 42.8%
2-y PFS 23.5%
Kinj et al. 2016 [49] M     53 60Gy/3f   1-y: 79.8%
2-y: 78.2%
  1-y OS: 83.8%;
2-y OS: 69.3%
Oskan et al. 2017 [50] M     40 26-60Gy/1-8f     1-y OS: 84%;
2-y OS: 73%
5-y OS: 39%
Pasqualetti et al. 2017 [54] M     33 24-27Gy/1f
27-42Gy/3f
    Median PFS:13.4 m
Jung et al. 2015 [48] M     50 40-60Gy/3-4f   1-y: 88.7%
3-y: 70.6%
  3-y OS: 64%
3-y PFS: 24%
Hamamoto et al. 2012 [46] P/M 144 128 31 14 48-60Gy/4-5f 2-y: 87% (P);
2-y: 50% (M)
   
Baschnagel et al. 2013 [37] M 32 0 32 10 48-60Gy/4-5f 1-y: 97%,
2-y: 92%,
3-y: 85%
2-y: 80% 1-y OS:83%,
2-y OS: 76%,
3-y OS-: 63%
 
Navarria et al. 2014 [52] M 76 0 76 29 48Gy/4f,
60Gy/8f, 60Gy/3f
1-y: 95%,
3-y: 89%.
Recurrence in 3 of 29 patients (locally and distance) 1-y OS: 84.1%,
3-y OS: 73%
 
Singh et al. 2014 [53] M 34 0 34 13 50Gy/5f 1-y: 95%,
2-y: 88%,
3-y: 80%.
All 5 patients with local recurrences had CRC   
Kim et al. 2009 [27] M 13 0   13 39-51Gy/3f   1-y; 76.9%,
2-y: 52.7%,
3-y: 52.7%
  1-y OS: 100%,
2-y OS; 75.5%,
3-y OS: 64.7%
Hof et al. 2007 [41] M 61 0 61 8 13-30Gy/1f 1-y: 88.6%,
2-y: 73.7%,
3-y: 63.1%
3-y: 0% 1-y OS: 78.4%,
2-y OS: 65.1%,
3-y OS: 47.8%
 
Nagata et al. 2002 [47] P/M 40 31 9 4 40-48Gy/4f 1-y: 100% (P);
2-y: 100% (P);
2 mtastases from colon relapsed at 6, 7 m   
Takeda et al. 2011 [39] P/M 162 113 34 15 50Gy/5f 1-y: 97% (P),
1-y: 86% (M)
2-y: 93% (P),
2-y: 82% (M)
1-y: 80%,
2-y: 72%
  
Okunieff et al. 2006 [17] M 50 0 50   50Gy/10f 1-y: 83% Had an unexpected number of local failures.   
Yamamoto et al. 2014 [56] P/M 201 164 37 29 45Gy/3f, 48Gy/4f, 60Gy/8f, 60Gy/15f 3-y: 78%(P),
5-y: 72% (P)
3-y: 26%,
5-y: 26%
3-y OS: 60.9%,
5-y OS: 38.1%
 
Helou et al. 2017 [55] M 120     48-52Gy/4-5f     
  1. P: primary NSCLC, M: metastatic lung tumor